Cantor Fitzgerald Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Neutral

Cantor Fitzgerald downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from an overweight rating to a neutral rating in a report released on Wednesday morning, Marketbeat.com reports. Cantor Fitzgerald currently has $36.00 target price on the specialty pharmaceutical company’s stock, down from their previous target price of $57.00.

Supernus Pharmaceuticals Stock Down 15.7 %

Supernus Pharmaceuticals stock opened at $33.52 on Wednesday. The company’s fifty day simple moving average is $37.58 and its 200-day simple moving average is $35.27. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a market cap of $1.85 billion, a P/E ratio of 31.33 and a beta of 0.90.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. The trade was a 48.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 9.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SUPN. Vident Advisory LLC boosted its holdings in Supernus Pharmaceuticals by 2.2% in the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock worth $520,000 after purchasing an additional 309 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 352 shares in the last quarter. Summit Investment Advisors Inc. boosted its holdings in Supernus Pharmaceuticals by 7.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock worth $190,000 after purchasing an additional 369 shares in the last quarter. Bank of Montreal Can boosted its holdings in Supernus Pharmaceuticals by 6.6% in the fourth quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock worth $275,000 after purchasing an additional 473 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in Supernus Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock worth $800,000 after purchasing an additional 560 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.